Drug Profile
Alpha-1 antitrypsin - Kamada
Alternative Names: A1AT; A1PI; AAT; AAT-IH; AAT-IV; Alpha-1 Antitrypsin; Alpha-1-Antiproteinase; alpha-1-proteinase inhibitor; ALPHA.1-PROTEINASE INHIBITOR HUMAN; Aralast; D1-AAT; G1-AAT; G1-AAT IV; Glassia; Infinia; Inhaled-AAT; IV AAT; Kamada-API; L1-AAT; Prolastin-CLatest Information Update: 04 Mar 2024
Price :
$50
*
At a glance
- Originator Kamada
- Developer Kamada; Mount Sinai Hospital (Toronto); Takeda
- Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Antiallergics; Antihyperglycaemics; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
- Mechanism of Action Immunomodulators; Serine endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Alpha 1-antitrypsin deficiency
- Discontinued Bronchiectasis; Cystic fibrosis; Graft-versus-host disease; Lung transplant rejection; Type 1 diabetes mellitus
Most Recent Events
- 01 Mar 2024 Launched for Alpha 1-antitrypsin deficiency in New Zealand (IV) (Martindale as viewed on 1 March 2024)
- 16 Aug 2023 Kamada receives positive scientific advice from the EMA regarding the confirmation of the overall design of the phase III InnovAATe trial in Alpha-1 antrypsin deficiency
- 16 May 2023 Registered for Alpha 1-antitrypsin deficiency in Switzerland (IV)